Beck, M.

patient study disease treatment syndrome mps ii vaccine antibody baseline group laronidase hurler syndrome pompe therapy month virus hurler rhgaa mps i diii-c enzyme infusion protein west nile virus hunter syndrome hunter development level 18 months diii-c-ap glycogen trial muscle titer swets blackwell 76157563 motor infantile-onset pompe disease glycosaminoglycan pediatrics death figure ap 205 vlps enzyme replacement therapy control group pompe disease dosage mucopolysaccharidosi conjugate vaccine conjugate assessment 18 patients idursulfase score change 52 weeks control result rhgaa treatment injection activity children symptom airway obstruction infection hospital domain iii 5 years survival analysis range safety replacement diagnosis /kg dosage diii-c-ap 205 wraith genzyme domain infantile-onset liver